Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Other Non-Current Liabilities: 2018-2024

Historic Other Non-Current Liabilities for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $1.1 million.

  • Bicycle Therapeutics' Other Non-Current Liabilities fell 81.67% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 81.67%. This contributed to the annual value of $1.1 million for FY2024, which is 75.52% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Other Non-Current Liabilities of $1.1 million as of FY2024, which was down 75.52% from $4.6 million recorded in FY2023.
  • In the past 5 years, Bicycle Therapeutics' Other Non-Current Liabilities ranged from a high of $4.6 million in FY2023 and a low of $1.1 million during FY2024.
  • For the 3-year period, Bicycle Therapeutics' Other Non-Current Liabilities averaged around $3.2 million, with its median value being $3.8 million (2022).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 30.88% in 2020, then plummeted by 75.52% in 2024.
  • Bicycle Therapeutics' Other Non-Current Liabilities (Yearly) stood at $2.6 million in 2020, then increased by 25.58% to $3.3 million in 2021, then increased by 16.77% to $3.8 million in 2022, then climbed by 19.59% to $4.6 million in 2023, then slumped by 75.52% to $1.1 million in 2024.